Zentalis Pharmaceuticals, Inc. (ZNTL): Depreciation & Amortization
$739.0K
Year ended 2025-12-31
$621.0K
Trailing 12 months to 2026-06-30
-19.7%
3-year compound annual growth
+35.8%
5-year compound annual growth
| Period ended | Depreciation & Amortization | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $739.0K | -42.7% | 2026-03-26, From 2025-01-01 |
| 2024-12-31 | $1.29M | -7.2% | 2026-03-26, From 2024-01-01 |
| 2023-12-31 | $1.39M | -2.6% | 2026-03-26, From 2023-01-01 |
| 2022-12-31 | $1.43M | +162.1% | 2025-03-26, From 2022-01-01 |
| 2021-12-31 | $544.0K | +240.0% | 2024-02-27, From 2021-01-01 |
| 2020-12-31 | $160.0K | +44.1% | 2023-03-01, From 2020-01-01 |
| 2019-12-31 | $111.0K | n/a | 2022-02-24, From 2019-01-01 |
Depreciation & Amortization at similar companies
| Company | Year ended | Depreciation & Amortization | Change YoY |
|---|---|---|---|
| Zentalis Pharmaceuticals, Inc. (ZNTL) | 2025-12-31 | $739.0K | -42.7% |
| Bristol Myers Squibb Co (BMY) | 2025-12-31 | $4.01B | -58.2% |
| TherapeuticsMD, Inc. (TXMD) | 2025-12-31 | $384.0K | -24.6% |
| Eli Lilly & Co (LLY) | 2025-12-31 | $2.00B | +13.0% |
| Pfizer Inc (PFE) | 2025-12-31 | $6.59B | -6.0% |
| Johnson & Johnson (JNJ) | 2025-12-28 | $7.50B | +2.2% |
| Nature's Sunshine Products Inc (NATR) | 2025-12-31 | $13.84M | -2.6% |
| Lisata Therapeutics, Inc. (LSTA) | 2025-12-31 | $146.0K | -16.1% |
| Heron Therapeutics, Inc. (HRTX) | 2025-12-31 | $2.31M | -7.1% |
Compare ZNTL, BMY, TXMD, LLY side by side · Screen every company in Pharmaceutical Preparations ↗